HELP
Cybin Inc. Common Stock
$10.01
-1.60
(-13.78%)
Mkt Cap
644.01M
Volume
3,113,695
52W Range
3.76-11.62
Sector
Healthcare
Beta
0.56
EPS (TTM)
-5.72 USD
P/E Ratio
-1.13
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | (44.68M) | 472,270 | 0 | 251,015 | 167,760 | 864,000 | 0 | 0 | 0 | 0 |
| Net Income | (147.05M) | (113.14M) | (78.08M) | (47.49M) | (67.63M) | (32.22M) | (1.94M) | (101,000) | (220,806) | (127,000) |
| EPS | -4.23 | -5.59 | -3.91 | -9.73 | -15.36 | -12.24 | -1.48 | -0.28 | -0.69 | -0.35 |
| Free Cash Flow | (133.79M) | (103.27M) | (69.62M) | (50.74M) | (45.73M) | (19.26M) | (1,384) | (118,785) | (247,026) | (7,185) |
| FCF / Share | -3.84 | -5.11 | -3.48 | -10.40 | -10.39 | -7.32 | -0.00 | -0.33 | -0.77 | -0.02 |
| Operating CF | (132.42M) | (101.30M) | (68.91M) | (47.43M) | (45.21M) | (19.03M) | (1,384) | (83,785) | (237,026) | 2,814 |
| Total Assets | 251.98M | 258.62M | 302.02M | 53.90M | 84.06M | 92.11M | 1.71M | 408,379 | 456,181 | 443,077 |
| Total Debt | 0 | 0 | 291,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 157.78M | 135.02M | 208.99M | 16.63M | 53.64M | 64.03M | 1.54M | 314,323 | 433,108 | 432,814 |
| Book Value | 232.24M | 237.20M | 291.93M | 48.23M | 76.16M | 86.12M | 1.45M | 394,726 | 440,250 | 292,784 |
| Return on Equity | -0.63 | -0.48 | -0.27 | -0.98 | -0.89 | -0.37 | -1.34 | -0.26 | -0.50 | -0.43 |
| Metric | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.99M) | (42.63M) | (47.03M) | (24.61M) | (30.58M) | (10.84M) | (56.90M) | (10.83M) | (21.35M) | (30.33M) | (11.89M) | (14.51M) |
| EPS | -0.92 | -1.76 | -1.94 | -1.10 | -1.46 | -0.54 | -2.84 | -0.55 | -1.07 | -3.45 | -1.93 | -2.68 |
| Free Cash Flow | (37.14M) | (32.30M) | (48.71M) | (21.86M) | (22.20M) | (27.05M) | (26.28M) | (20.06M) | (20.92M) | (26.21M) | (11.72M) | (10.76M) |
| FCF / Share | -0.74 | -1.33 | -2.01 | -0.98 | -1.06 | -1.35 | -1.31 | -1.02 | -1.05 | -2.99 | -1.90 | -1.98 |
| Operating CF | (36.82M) | (31.92M) | (48.10M) | (21.69M) | (21.11M) | (26.74M) | (25.94M) | (19.89M) | (20.71M) | (26.04M) | (11.46M) | (10.70M) |
| Total Assets | 350.27M | 289.88M | 252.79M | 154.73M | 258.62M | 253.55M | 262.39M | 284.65M | 302.02M | 129.72M | 57.63M | 45.69M |
| Total Debt | 0 | 0 | 40.29M | 32.66M | 0 | 0 | 133,000 | 212,000 | 291,000 | 366,000 | 0 | 0 |
| Cash & Equiv | 219.31M | 194.97M | 116.81M | 87.12M | 135.02M | 136.29M | 154.32M | 183.28M | 208.99M | 39.00M | 18.12M | 9.35M |
| Book Value | 323.25M | 273.71M | 193.86M | 111.39M | 237.20M | 240.24M | 255.02M | 279.83M | 291.93M | 121.22M | 48.38M | 39.69M |
| Return on Equity | -0.15 | -0.16 | -0.24 | -0.22 | -0.13 | -0.05 | -0.22 | -0.04 | -0.07 | -0.25 | -0.25 | -0.37 |
HELP News
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Cybin: A Speculative Bet On Their Pivotal Depression Readout
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
Helus Pharma™ Announces US$50 Million Underwritten Offering
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress